Eisai and Merck Receive Complete Response Letter for LENVIMA and KEYTRUDA Combination

Merck and Eisai received a Complete Response Letter for their application seeking first-line approval of LENVIMA plus KEYTRUDA for patients with unresectable hepatocellular carcinoma. The letter means the application was not approved at this time; the companies are reviewing its contents and assessing next steps. The article reports no financial figures or stock-price impact.